Cathie Wood's ARK Invest executed a series of trades across its exchange-traded funds on Monday, October 5, 2026, releasing details of the transactions on Tuesday morning through its daily trade disclosures. ARK Invest, the asset manager founded by Cathie Wood, is known for its actively managed, innovation-focused ETFs, including the flagship ARK Innovation ETF (ARKK) and the ARK Genomic Revolution ETF (ARKG). The firm reduced its stakes in Twist Bioscience, 10x Genomics, and CareDx, while adding to positions in Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte.

Twist Bioscience Sale Continues

ARK sold 90,713 shares of Twist Bioscience through its ARKK and ARKG funds, a stake valued at approximately $17.1 million. The sale was not the firm's first disposition of the stock this month, as ARK also sold 46,931 Twist shares on September 29. All told, the firm has sold roughly $6 million worth of Twist Bioscience shares through its ARKG fund over the past few weeks.

The selling came as Twist Bioscience shares rose 8.7% on Monday. The stock has gained more than 60% over the past month, a rally that has been linked to the company's synthetic-DNA platform. Twist also holds an agreement to support Eli Lilly's TuneLab AI drug-discovery platform.

What ARK Bought

The firm's largest purchase of the session was Recursion Pharmaceuticals, which trades under the ticker RXRX. ARK bought 1,482,357 shares worth about $6.1 million through the ARKK and ARKG funds. Recursion is a pharmaceutical company that applies artificial intelligence to drug discovery. Its shares rose more than 16% on Monday. The company recently extended a data-licensing deal with Tempus through 2029, and analysts maintain a 12-month price target of $7.22 on the stock, according to Koyfin. Data-licensing arrangements like that Tempus extension — and Twist's TuneLab agreement with Eli Lilly — illustrate how large pharmaceutical companies now source AI-driven discovery capabilities from specialized genomics and data firms, the model connecting several of the names in Monday's trade list.

ARK also purchased 96,308 shares of Intellia Therapeutics for approximately $1.18 million, building on a series of earlier purchases. The firm has acquired more than 1,178,000 Intellia shares since September 29. Intellia, a clinical-stage gene-editing company developing CRISPR-based therapies, is awaiting a decision from the U.S. Food and Drug Administration on its lead therapy, which treats hereditary angioedema, with the decision date set for March 10, 2027. Barclays initiated coverage of the company with an “Underweight” rating and set an $8 price target, which represent a 36% decline from current levels.

In addition, ARK bought 115,472 shares of Veracyte through its ARKG fund in a purchase worth about $5.29 million. Veracyte recently reported Phase 3 trial data showing that its Decipher Prostate test can help identify prostate cancer patients who may benefit from adding hormone therapy to radiation treatment.

What ARK Sold

Along with Twist Bioscience, ARK sold shares of two other companies on Monday. The firm sold 27,277 shares of 10x Genomics — a supplier of instruments and consumables for single-cell and spatial genomics research — for approximately $2.55 million, and 22,271 shares of CareDx, a diagnostics company centered on organ-transplant monitoring, valued at about $1.5 million.

Shares of both companies rose on Monday. 10x Genomics gained 4.5% and has advanced more than 48% over the past month, while CareDx rose 4% to its highest level in more than four years.

ARK continues to release its daily trade data each morning, providing regular visibility into buy and sell activity across its funds.

Source: CoinCentral